Clinical Trial

Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris

Name: Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris — clinical trial record (NCT05646563)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 in PNH patients undergoing complement-inhibitor therapy with Soliris.

Protocol Amendment History 6 amendments

This ClinicalTrials.gov record has been amended 6 times since 2022-12-03; most recent amendment 2026-04-07.

Trial Details

NCT Number	NCT05646563
Lead Sponsor	NovelMed Therapeutics
Conditions	Paroxysmal Nocturnal Hemoglobinuria
Enrollment	12 participants
Start Date	2027-01
Primary Completion	2029-07 (estimated)
Study Completion	2030-08 (estimated)
Updated on ClinicalTrials.gov	2026-04-13